# Mark Krul

> Mark Krul is a seed investor at Aglaia BioMedical Ventures backing Biotechnology. See 1 investments, check sizes, portfolio. Updated Aug 2026.

- Type: Angel Investor
- Fund: [Aglaia BioMedical Ventures](https://shizune.co/investors/profile/aglaia-biomedical-ventures)
- Location: Utrecht, The Netherlands
- Total investments: 1
- Last investment: Dec 2015
- Lead investor: 0%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/in/markkrul/

Mark Krul is a seed investor at Aglaia BioMedical Ventures in Utrecht focused on Biotechnology and Pharmaceutical. Mark Krul

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 1 | 100% |
| Pharmaceutical | 1 | 100% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Inthera Bioscience | Inthera Bioscience is a Switzerland-based private biopharmaceutical company developing targeted small molecule therapies for solid tumors. It is focused on developing inhibitors of intracellular protein-protein interactions employing a proprietary technology platform. The company is headquartered in Zürich, Switzerland. | $3.7M | Seed | Dec 14, 2015 |  |

1 of 1 investments shown.

## Co-investors
- [Microsoft Accelerator](https://shizune.co/investors/profile/microsoft-ventures) — VC Fund, 1 deal together
- [Novo Holdings](https://shizune.co/investors/profile/novo-a-s) — VC Fund, 1 deal together

## About Aglaia BioMedical Ventures

VC Fund · Bilthoven, The Netherlands

Aglaia is founded on the principle that the willingness to take risks on the very early stage ventures of today results in opportunities that may grow into the winning companies of tomorrow. As such, we are typically the first provider of capital for startup and early stage companies and a driving force behind product development. Since thenumber of technological discoveries in the biomedical field is growing fast, specialized knowledge regarding the translation of these discoveries into novel products is a prerequisite for success. Aglaia's focus on oncology is considered to be a differentiating asset. We invest in novel tools and technologies as well as components of contemporary drug development.Opportunities may be derived from research centers as well as from corporate spinouts. We select, develop and commercialize promising technologies up to a level where the technology becomes attractive to larger investors or pharmaceutical and biotech companies.

1 contacts available at Aglaia BioMedical Ventures.

| Name | Title | Profile |
| --- | --- | --- |
| Mark Krul | Partner | https://shizune.co/investors/profile/mark-krul |

## Similar investors

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [Right Side Capital Management](https://shizune.co/investors/profile/right-side-capital-management) — VC Fund

## FAQ

### What does Mark Krul invest in?

Mark Krul invests primarily in Biotechnology and Pharmaceutical startups, most often at Seed stage. Most of the 1 investments tracked by Shizune back companies in Switzerland. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did Mark Krul last invest?

The most recent investment recorded for Mark Krul closed in Dec 2015. Shizune tracks 1 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co